Identification of Potential Biomarkers for Pain
| Status: | Recruiting |
|---|---|
| Conditions: | Fibromyalgia, Pain |
| Therapuetic Areas: | Musculoskeletal, Rheumatology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/17/2018 |
| Start Date: | May 2018 |
| End Date: | September 30, 2021 |
| Contact: | Lauren Fedor, CCRP |
| Email: | fedor@rowan.edu |
| Phone: | 856-566-6003 |
Development of a Serum Biomarker-Based Approach to Monitor Opioid Adherence and Minimize Substance Misuse in Chronic Pain Management
The study investigates the potential of using serum biomarkers to assess pain in fibromyalgia
patients.
patients.
At the heart of the opioid epidemic is the lack of an objective measure of pain, which will
help evaluate the validity of the patients' perception that the current dosage of opioid is
sufficient of insufficient to alleviate pain. This study will test the quantifiable proteins
such as S100B and BDNF will serve as objective measures (biomarkers) of pain.
Fibromyalgia patients will be recruited into two groups-- one that uses opioids and the other
that does not. Blood will be collected every 6 months for two years. The serum will be used
to assay for levels of S100B and BDNF, The pressure-pain threshold (PPT) data, as part of
standard of care, will also be collected. Correlation will the be assessed.
help evaluate the validity of the patients' perception that the current dosage of opioid is
sufficient of insufficient to alleviate pain. This study will test the quantifiable proteins
such as S100B and BDNF will serve as objective measures (biomarkers) of pain.
Fibromyalgia patients will be recruited into two groups-- one that uses opioids and the other
that does not. Blood will be collected every 6 months for two years. The serum will be used
to assay for levels of S100B and BDNF, The pressure-pain threshold (PPT) data, as part of
standard of care, will also be collected. Correlation will the be assessed.
Inclusion Criteria:
- Diagnosed with Fibromyalgia
Exclusion Criteria:
- Evidence of a history of substance abuse, neurological or oncologic disease, ischemic
heart disease, kidney or hepatic insufficiency.
We found this trial at
1
site
Click here to add this to my saved trials
